Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149871 (deep vein thrombosis)
 12,364 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Protein C (PC) is the zymogen of an anticoagulant serine protease and is converted to its active form (activated protein C: APC) by thrombin in the presence of thrombomodulin. APC plays an important role in regulating blood coagulation and fibrinolysis by inhibiting not only blood coagulation factors Va and VIIIa but also type-1 plasminogen activator inhibitor (PAI-1). In this study, it was reported that the antithrombotic effect of a human APC product (designated as CTC-111) compared with that of heparin and human PC on the deep venous thrombosis (DVT) model induced in mice by stasis caused by inferior vena cava ligation and operative invasion. Drugs were injected into a tail vein at -2, 30, 60, and 120 min after the inferior vena cava ligation. One-fifth amount of the total dosage of a given drug was injected at each time point. The wet weight of thrombus formed was reduced by APC or heparin administration, however, PC, which was equal to APC in protein amount, did not show any antithrombotic effect. To confirm whether human PC could be activated by mouse thrombin, PC was treated with mouse or human thrombin to measure the amount of APC formed. Mouse thrombin could activate human PC at a similar activation rate as human thrombin. These results suggest that externally administrated PC cannot exhibit antithrombotic effect in this DVT model due to slow activation rate to APC and that APC is a better antithrombic agent than PC for treating thrombotic diseases.
 ...
PMID:Effect of activated human protein C on experimental venous thrombosis induced by stasis with operative invasion in mice. 1099 52

Teijin and Chemo-Sero are codeveloping CTC-111 as a treatment for disseminated intravascular coagulation (DIC) due to protein C deficiency. The drug was launched for the treatment of protein C deficiency in Japan on January 31, 2001 and as of October 2001 was awaiting approval for the treatment of DIC, also in Japan [426762]. CTC-111 was evaluated in a multicenter pharmacokinetic trial in venous thrombosis patients with inherited protein C deficiency. CTC-111 was effective in six of ten patients with venous thrombosis, six of seven patients with deep vein thrombosis and two of three patients with pulmonary embolism. Treatment was safe and effective and there were no serious adverse events [350149].
 ...
PMID:CTC-11 (Teijin). 1595 88